baber/WOPTO huggingface dataset:
Patent NZ-563928-A (NZ)
Title: Heating apparatus
Inventor: GEBHARDT PETER
Filed: 2007-11-30
Abstract: A heating apparatus having a boiler connected to a heat exchanger. Liquid exchange between the boiler and the heat exchanger takes place solely as a result of convection. The heat exchanger has flowing through it on the primary side a heat transport medium which is heated by a heat source with a lower temperature than the hot side of the boiler and is evaporated. The heat transport medium is subsequently compressed by a compressor regulated according to rotational speed and is supplied to a primary side of the heat exchanger. In this case, the heat transport medium discharges its entire evaporation heat to the boiler. The condensed heat transport medium subsequently flows back to the heat source. To achieve high efficiency, the compressor is controlled by a regulating device connected to sense the temperature of the heat transport medium and/or the temperature of the hot side of the heat exchanger.
Patent NZ-564942-A (NZ)
Title: Flocculant and method for manufacturing same
Inventor: WADA SHINICHIRO
IPC: C01B33/26
Filed: 2008-01-07
Abstract: Disclosed is a solution for use as a flocculant, including water, unit particles of hydrous aluminium silicate obtained by breaking down aggregates (such as by sonication) of mineral particles in a mineral raw material (such as kaolin), wherein the hydrous aluminium silicate in the unit particles has the same structure as in the mineral raw material, characterised in that the solution includes a pH adjuster to ensure that the unit particles remain dispersed or loosely associated with one another in the water. Also disclosed is a method of manufacturing a solution for use as a flocculant, including the steps of: (a) collecting a mineral raw material, wherein the mineral raw material includes aggregates of hydrous aluminium silicate; (b) mixing the mineral raw material with water; (c) breaking down the mineral raw material to obtain unit particles of hydrous aluminium silicate; wherein the step of breaking down the mineral particles ensures that the unit particles of hydrous aluminium silicate retains the same structure as in the mineral raw material; the method characterised by the step of: (d) Adding a pH adjuster to the solution to ensure that the unit particles remain dispersed or loosely associated with one another in the water.
Patent NZ-567229-A (NZ)
Title: Package for containers
Inventor: SUTHERLAND ROBERT L
IPC: B65D71/46
Filed: 2006-10-05
Abstract: A bottle package (and a blank for forming the package) includes a carton which has a set of foldable upper struts 81 and a set of foldable lower struts 101 arranged alongside the bottle top apertures 85, 105 in the bottom panel 30 of the carton so that the edges of the horizontal folded top 84 of the upper struts upstanding via the vertical portions 86 of the upper struts from the main bottom panel lie beneath the flanges 175 of the pair of containers the tops of which project up through the apertures in the bottom panel. The lower struts 101 are folded so that a projection on the free end 114 of the lower strut 104 projects through a receiving aperture 90 provided in the upper strut 84.
Patent NZ-571144-A (NZ)
Title: Association between terutroban (3-[6(R)-(4-chlorophenylsulfonamido)-2-methyl-5,6,7,8-tetrahydronaphth-1-yl]propionic acid or S18886) and an ACE inhibitor such as perindopril or ramipril
Inventor: VERBEUREN TONY
IPC: A61K31/40
Filed: 2008-09-10
Abstract: Disclosed is a combination of terutroban of formula (I), optionally in the form of an optical isomer or one of its pharmaceutically acceptable salts, and an angiotensin-converting enzyme inhibitor (ACE inhibitor) such as perindopril or one of its pharmaceutically acceptable salts. The combination is useful for the treatment of vascular complications associated with diabetes, atherothrombotic diseases, hyperlipidaemia, hypertension, chronic venous diseases, inflammation, metabolic syndrome associated with obesity and cancer.
Patent NZ-572020-A (NZ)
Title: Semiconductor device with surge current protection and method of making the same
Inventor: SANKIN IGOR
IPC: H01L29/868
Filed: 2007-05-01
Abstract: A wide bandgap semiconductor device with surge current protection and a method of making the device are described. The device comprises a low doped n-type region formed by plasma etching through the first epitaxial layer grown on a heavily doped n-type substrate and a plurality of heavily doped p-type regions formed by plasma etching through the second epitaxial layer grown on the first epitaxial layer. Ohmic contacts are formed on p-type regions and on the backside of the n-type substrate. Schottky contacts are formed on the top surface of the n-type region. At normal operating conditions, the current in the device flows through the Schottky contacts. The device, however, is capable of withstanding extremely high current densities due to conductivity modulation caused by minority carrier injection from p-type regions.
Patent NZ-576277-A (NZ)
Title: Liquid anti-rabies antibody formulations
Inventor: BAKKER ALEXANDER BERTHOLD HENDRIK
IPC: A61K9/00
Filed: 2007-12-04
Abstract: Disclosed is a pharmaceutical formulation of anti-rabies monoclonal antibodies that is stable for at least 12 months at a temperature between substantially 2°C to substantially 8°C, the formulation comprising: (i) anti-rabies virus monoclonal antibody CR57 (heavy chain SEQ ID NO: 1 and light chain SEQ ID NO: 2), or an antibody that is at least 95% homologous in sequence thereto and is capable of competing for binding to a target recognized by CR57 and having rabies virus neutralizing activity; and (ii) anti-rabies virus monoclonal antibody CR4098 (heavy chain SEQ ID NO: 3 and light chain SEQ ID NO: 4), or an antibody that is at least 95% homologous in sequence thereto and is capable of competing for binding to a target recognized by CR4098 and having rabies virus neutralizing activity; wherein the formulation comprises a citrate buffer at a concentration from substantially 5 mM to substantially 25 mM, sodium chloride at a concentration from substantially 50 mM to substantially 250 mM, and a surfactant. Also disclosed is the use the formulation in the manufacture of a medicament for prophylaxis treatment of a subject exposed to rabies.
Patent NZ-579685-A (NZ)
Title: Laminated board with corrugated 2 ply internal structure and method for manufacturing
Inventor: ADIE VICTOR
IPC: B32B37/20
Filed: 2008-02-14
Abstract: A high bulk four ply laminated board for use in the production of large displays, show-cards or graphic panels, and the apparatus and method of manufacture. The inner plies or sheets are embossed to produce raised projections or bumps in a regular checkerboard pattern. Glue or adhesive is applied to the inner surfaces of the embossed leaves then the two sheets are pressed or rolled together so they adhere by connecting the elevated projections into a composite ply. The outer surfaces of the composite ply are simultaneously covered by print quality flat sheets coated in adhesive to form a high bulk laminated board. When making the composite ply, the peaks of one ply can be aligned with the valleys of the second sheet. Steam, heat and pressure can be used to assist embossing. An additional flat leaf can be inserted and adhered between the two embossed layers to form the composite core.
Patent NZ-580559-A (NZ)
Title: Male contact for optical fibre with an elongated floating ferule extending through a front of an elastically deformable body
Inventor: HAMBLIN CHRISTOPHER
IPC: G02B6/38
Filed: 2008-05-07
Abstract: Disclosed is a male contact for optical fiber. The male contact includes an outer body of an elastically deformable material, a cylindrical guide having a front portion attached to a rear portion of the outer body and a rear portion protruding from the rear portion of the outer body. The male contact also includes a cable adapter extending through the cylindrical guide and an elongated floating ferrule equipped with a fiber segment. The ferrule extending through a front portion of the outer body and being connected to a tubular ferrule holder movably mounted in the outer body and having abutment means for bearing on first shoulders positioned between the front and rear portions of the outer body. The male contact further includes a helical spring provided between the front portion of the cylindrical guide and the abutment means of the ferrule holder pushing the abutment means of the ferrule holder against the first shoulders of the outer body. The cylindrical guide comprises a first cylindrical body provided with abutment means for engaging with second shoulders of the outer body situated between the first shoulders and the rear portion of the outer body and an annular shoulder bearing against the edge of the rear portion of the outer body. The first cylindrical body comprises an inner shoulder. The cable adapter is mounted to slide inside the first body. The cable adapter is provided with an annular shoulder situated downstream of the front portion of the first cylindrical body providing a housing therein for a helical spring bearing on the annular shoulder of the cable adapter and on the inner shoulder of the first cylindrical body pushing the cable adapter toward the rear end of the ferrule. The cable adapter is provided on its part located outside the first cylindrical body with a removable abutment bearing against the edge of the rear portion of the cylindrical guide keeping the helical spring situated inside the first cylindrical body compressed and allowing the cable adapter to float inside the cylindrical guide after the removable abutment is removed.
Patent NZ-583187-A (NZ)
Title: Pyridazinone derivatives
Inventor: DORSCH DIETER
IPC: C07D413/10
Filed: 2008-04-29
Abstract: Disclosed are pyridazinone derivative compounds of the formula (I) in which the variables R1, R2, R3, R4, R4' are each as defined in the specification. The disclosure also relates to the use of these compounds in which the inhibition, regulation and/or modulation of signal transduction by kinases, in particular tyrosine kinases and/or serine/threonine kinases, plays a role, furthermore to pharmaceutical compositions which comprise these compounds, and to the use of the compounds for the treatment of kinase-induced diseases. In particular, these compounds are suitable where inhibition, regulation and/or modulation of signal transduction by Met kinase plays a role. Since these compounds are inhibitors of tyrosine kinases, especially of Met kinase, they can be used, inter alia, for treatment of tumours.
Patent NZ-584404-A (NZ)
Title: Desk Organizer
Inventor: RANBY DAVID BRUCE
IPC: A45C11/00
Filed: 2011-03-16
Abstract: Disclosed is a desk organizer adapted to be located on a desk defining a horizontal plane between a computer screen and keyboard to locate stationery items without interrupting viewing of the computer screen and operation of the keyboard. The desk organizer includes an elongate body, shaped to face a user with the longitudinal dimension being oriented when in use parallel to a longitudinal dimension of the keyboard and the body being curved or angled in the horizontal plane. There is an upper inclined body surface facing the user and a lower body surface to face and abut a support surface. The upper and lower surfaces separated by a depth dimension. The upper surface including at least one recess to removably locate stationery items therein and at least one device support surface to support an IT device. The dimension extending from the device support surface to an adjacent rear face of the back of the elongate body of the desk organizer is dimensioned such that a user can both secure and operate the IT device with at least one hand. The fingers can be located on the back and the thumb located on the front to operate the IT device.
Patent NZ-585620-A (NZ)
Title: Compositions and methods for enhancing immune response
Inventor: JOHNSTON JAMES
IPC: A61P37/04
Filed: 2008-10-23
Abstract: Disclosed herein is the use of oxidatively transformed carotenoid for the preparation of a medicament for the enhancement of the adaptive immune response to an antigen in a subject being immunized, wherein said oxidatively transformed carotenoid is a mixture formed by reaction of 6 to 8 molar equivalents of oxygen with a carotenoid and contains a polymeric component, and wherein said infection is selected from the group consisting of community acquired pneumonia, upper and lower respiratory tract infection, skin and soft tissue infection, acute bacterial otitis media, bacterial pneumonia, pyelonephritis, intra-abdominal infection, bacterial sepsis, central nervous system infection, bacteremia, wound infection, peritonitis, meningitis, infections after burn, urogenital tract infection, pelvic inflammatory disease, endocarditis, and intravascular infection. . Also disclosed is a pharmaceutical composition comprising oxidatively transformed carotenoid and an antigen, wherein said oxidatively transformed carotenoid is a mixture formed by reaction of 6 to 8 molar equivalents of oxygen with a carotenoid and contains a polymeric component.
Patent NZ-586730-A (NZ)
Title: Equipment room with bristle lined vertical inlet air filter duct
Inventor: TINDALE PATRICK
IPC: B01D46/28
Filed: 2009-01-16
Abstract: An equipment room (110) comprising an air filter (111), the air filter comprising a duct forming a passageway (118, 120) extending between an inlet (116) and an outlet (113) of the air filter. The duct includes bristles extending from a wall of the duct across at least a portion of the passageway so as to remove entrained particles from air passing through the duct. The duct includes an inlet passageway (118) in series with an outlet passageway (120). The inlet passageway is lined with bristles extending across the inlet passageway over at least a portion of a length thereof. The inlet passageway is arranged to allow air to be drawn into the equipment room vertically upwards through the inlet passageway from an exterior environment (117) and towards an interior (115) of the room.
Patent NZ-589623-A (NZ)
Title: Communications cable with fabric sleeve
Inventor: ALLEN JERRY
IPC: H02G1/08
Filed: 2009-06-01
Abstract: A communications cable (11) is provided with a pliant sleeve (31) to allow it to be more easily inserted into a conduit. The sleeve (31) has a means to engage and attach to the cable (11) such as an adhesive (33). The sleeve (31) is made of a material which provides less friction than a casing of the cable (11) to reduce damage to the cable (11) during installation into a conduit, particularly a small diameter conduit.
Patent NZ-595182-A (NZ)
Title: Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
Inventor: BALLENTINE SHELLEY K
IPC: A61K31/497
Filed: 2006-10-17
Abstract: Disclosed is the use of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof in the preparation of a medicament for use in a method for treating or preventing a hematological malignancy, by reducing kinase activity of FLT3, provided the hematological malignancy is not hairy cell leukaemia, and provided that said use does not include use of a famesyl transferase inhibitor; and wherein said method optionally comprises administration of a chemotherapeutic agent, gene therapy, immunotherapy or radiation therapy.
Patent NZ-597985-A (NZ)
Title: Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
Inventor: GANGWAR SANJEEV
IPC: A61K47/48
Filed: 2010-08-02
Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
Patent NZ-599338-A (NZ)
Title: Complexes of il-15 and il-15ralpha and uses thereof
Inventor: PAVLAKIS GEORGE N
IPC: A61K39/00
Filed: 2008-06-27
Abstract: NZ 599338 Disclosed is an isolated cell that recombinantly expresses a mammalian interleukin (IL-15); and a mammalian interleukin-15 receptor alpha (IL-15Ra), a soluble form of a mammalian IL-15Ra, a polypeptide comprising a mammalian IL-15Ra and a first heterologous molecule, or a polypeptide comprising a soluble form of a mammalian IL-15Ra and a second heterologous molecule, wherein the cell expresses at least 0.15 pg of mammalian IL-15 per day when cultured in serum-free media, and wherein the cell is not a human totipotent stem cell.
Patent NZ-600938-A (NZ)
Title: Control system for an electric power system
Inventor: BUSH STEPHEN FRANCIS
IPC: B60L9/00
Filed: 2012-06-27
Abstract: Disclosed is a control system (116) for an electric power supply system. The control system (116) is comprised of a wireless communication system (120) and a controller. The wireless communication system (120) is configured to track one or more electric vehicles (112) in a vicinity of a control system (120) and to communicate battery charge data of the one or more electric vehicles (112) and load data of an electric power system. The controller is communicatively coupled to the wireless communication system (120) and configured to receive the battery charge data of the one or more electric vehicles (112) and the load data of the electric power system. The controller is further configured to operate one or more protection elements of the electric power system based on the charge data of the one or more electric vehicles (112) and the load data of the electric power system.
Patent NZ-603498-A (NZ)
Title: Human cytomegalovirus neutralizing antibodies and use thereof
Inventor: LANZAVECCHIA ANTONIO
IPC: C07K16/08
Filed: 2009-07-15
Abstract: NZ 603498 Disclosed is an isolated antibody, or an antigen binding fragment thereof, that is specific for a human cytomegalovirus (hCMV) protein gB, wherein the antibody or fragment comprises heavy and light chain variable regions as defined in the complete specification. Also disclosed is the use of said antibody in the manufacture of a medicament for the treatment of hCMV infection.
Patent NZ-611628-A (NZ)
Title: Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
Inventor: TARCIC NORA
IPC: A61K31/47
Filed: 2011-12-06
Abstract: Discloses use of laquinimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament formulated as a pharmaceutical oral dosage form for reducing or inhibiting progression of the level of fatigue, deterioration of functional status or deterioration of general health in a multiple sclerosis human patient who is assessed to be afflicted with fatigue, deterioration of functional status or deterioration of general health wherein laquinimod is formulated to be administered daily over a period of greater than 24 weeks. Also discloses use of laquinimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament formulated as a pharmaceutical oral dosage form for providing neuroprotection to a human subject.
Patent NZ-618892-A (NZ)
Title: Pap system
Inventor: FORMICA JUSTIN JOHN
IPC: A61M16/00
Filed: 2012-06-21
Abstract: A PAP system includes a PAP device to generate a supply of pressurized air, a patient interface adapted to form a seal with the patient’s face, air delivery tubing to interconnect the patient interface and the PAP device, and a cover that substantially encloses at least a portion of the PAP device and a portion of the air delivery tubing. The cover includes a wrap or scarf-like arrangement including a headgear strap portion that cooperates with another headgear strap adapted to wrap entirely around the patient’s head to stabilize and support the system on the patient’s head.
Patent NZ-630643-A (NZ)
Title: Pharmaceutical compositions comprising fatty acid esters
Inventor: HICKEY MAGALI B
IPC: A61P25/18
Filed: 2013-03-13
Abstract: Disclosed is injectable pharmaceutical compositions comprising: (a) a water-insoluble antipsychotic agent; (b) a C1-6 alkyl ester of a C10-20 fatty acid; (c) a polyoxy ethylene derivative of a sorbitan ester of a carboxylic acid, wherein the carboxylic acid comprises 8-20 carbon atoms; and (d) an aqueous vehicle; wherein the composition forms an aqueous, flocculated, injectable suspension. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs such as aripiprazole and olanzapine.
Patent NZ-700824-A (NZ)
Title: Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
Inventor: QUINN ANTHONY
IPC: A61P3/06
Filed: 2011-09-09
Abstract: Disclosed is the use of recombinant human lysosomal acid lipase (LAL) for the manufacture of a medicament for the treatment of a human patient suffering from LAL deficiency, wherein the medicament is for administration at: a. one or more initial doses of 1 mg LAL/kg body weight or less; and b. one or more maintenance doses greater than 1 mg LAL/kg body weight, and wherein the medicament is for administration one time about every 5 days to one time about every 30 days.
Patent NZ-711247-A (NZ)
Title: Child resistant zipper closure for recloseable pouch with double slider and methods
Inventor: DOWLER ROGER E
IPC: B65D33/25
Filed: 2014-03-11
Abstract: A double slider for a plastic zipper closure to increase the difficulty for children to open the zipper closure includes a male track and a female track having interlocking male and female profiles; a first slider and a second slider that are selectively releasably connected together between an engaged position and a disengaged position. In the engaged position, the first and second sliders move together along the top edges of the track, and the opening end of the first slider body is against the first end of the second slider body; and in the disengaged position, the first and second sliders move independent of each other along the top edges of the track.
Patent NZ-714267-A (NZ)
Title: Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
Inventor: RABOISSON PIERRE JEAN-MARIE BERNARD
IPC: C07D487/04
Filed: 2014-06-26
Abstract: This invention concerns pyrrolo[3,2-d]pyrimidine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treatment and /or therapy of diseases.
Patent NZ-722518-A (NZ)
Title: Il-21 antibodies
Inventor: DAVIES JULIAN
IPC: C07K16/24
Filed: 2015-03-13
Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.
Patent NZ-732522-A (NZ)
Title: Textile patient interface
Inventor: FORMICA JUSTIN JOHN
IPC: A61M16/06
Filed: 2015-11-26
Abstract: A patient interface for sealed delivery of a flow of air to an entrance of a patient’s airways, including at least the nares (3101) of the patient comprising: a plenum chamber (3200); and a seal forming structure (3100) comprising: a foam undercushion (3114) structured to releasably engage with the plenum chamber; and an air-impermeable textile membrane (3109) configured to contact the face of the patient during use, the air-impermeable textile membrane having an outer periphery that is joined to the foam undercushion by an airtight bond and an inner portion that lies freely on the foam undercushion such that the inner portion of the air-impermeable textile membrane is separable from the foam undercushion by the flow of air in use. The invention provides a seal forming structure that is comfortable for the user with less leakage of supplied air.